Ovarian Cancer

A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.

Expression of mesothelium vascular cell adhesion molecule-1 (VCAM-1) is associated with poorer overall and progression-free survival in patients with epithelial ovarian cancer, according to a retrospective analysis.

The use of surveillance did not affect survival among women with stage I malignant ovarian germ cell tumors, according to a new retrospective analysis.

Adding the WEE1 inhibitor AZD1775 to carboplatin offered enhanced response rates in women with TP53-mutated ovarian cancer that was refractory or resistant to first-line platinum-based therapy in a phase II study.

Adding seribantumab to paclitaxel failed to improved progression-free survival in unselected patients with platinum-resistant or -refractory ovarian cancer. Expression of heregulin and HER2, however, could identify a subset of patients that derive benefit from the therapy.

The oral PARP inhibitor rucaparib showed strong activity and an acceptable safety profile in women with high-grade, BRCA-mutated ovarian carcinoma who had previously received at least two lines of chemotherapy.

The oral PARP inhibitor niraparib yielded significantly improved progression-free survival for women with platinum-sensitive, recurrent ovarian cancer in a phase III trial.

Here we review current guidelines on breast and ovarian cancer screening, prophylactic surgery, and other risk-reduction strategies in patients with these mutations, and we detail the data that drive these recommendations.

For some time, genetic testing has been predictive and prognostic. It is now assuming a therapeutic role as well. An example is the targeting of breast cancer patients with BRCA mutations for treatment with PARP inhibitors.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that found that surveillance with CA-125 in ovarian cancer patients led to more use of chemotherapy, decreased quality of life, and no improvement in survival.

The FDA issued a recommendation against the use of any currently available screening tests for ovarian cancer.

Ovarian cancer mortality rates declined significantly in several parts of the world from 2002 to 2012, according to a new study. Among the main reasons for the decline is the use of oral contraceptives, particular in the United States and European Union.

The use of telephone counseling for hereditary breast and ovarian cancer was noninferior to in-person counseling with no significant adverse effects on long-term outcomes.

This video explores a study that found telephone-based genetic counseling for women at risk of hereditary breast and ovarian cancers was noninferior to in-person counseling, with no significant adverse effects on long-term outcomes.

Over a 10-year period, the use of neoadjuvant chemotherapy increased significantly in women with advanced ovarian cancer, according to a new observational study.

In a new practice guideline, the American Society of Clinical Oncology offered recommendations on the use of neoadjuvant chemotherapy and interval cytoreduction for women with stage IIIC or IV epithelial ovarian cancer.

A study found that follicle-stimulating hormone receptors are expressed in many ovarian tumors, and not in normal ovarian tissue, thus representing a promising therapeutic target.

A new study is suggesting that combining BET inhibitors with other agents targeting protein kinases might make them more effective in treating cancer.

Low-grade serous ovarian cancer is a rare, slow-growing cancer that is generally resistant to cytotoxic chemotherapy. In the upfront setting, treatment recommendations mimic those of high-grade serous ovarian cancer.

Elevated levels of neopterin were found to be significantly associated with poorer survival outcomes in patients with ovarian cancer.

Researchers are hoping that adding a checkpoint inhibitor to the treatment armamentarium may help improve outcomes in patients with locally advanced or metastatic disease epithelial ovarian cancer.

A large, prospective analysis showed that risk factors for ovarian cancer demonstrate substantial heterogeneity in their associations with histologic subtypes of the disease.

In this video Dr. Odunsi discusses a new study that found that higher T-cell diversity in ovarian cancer is associated with poor overall survival.

Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.

Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.

Hormone maintenance therapy is associated with better survival than post-treatment surveillance for women with low-grade serous carcinoma of the ovary or peritoneum.

Among women previously treated with neoadjuvant chemotherapy followed by debulking surgery for advanced epithelial ovarian cancer, adding intraperitoneal to intravenous administration of postsurgical chemotherapy appears to be associated with a lower rate of disease progression.

NEW ORLEANS – A new type of antibody-drug conjugate (ADC) platform may pave the way to help patients with ovarian cancer and non-small cell lung cancer.

Combining three markers of homologous recombination deficiency into a single score may improve treatment decisions for women with ovarian cancer, according to a study reported at the 2016 SGO Annual Meeting.